Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Intellia Therapeutics has raised $400.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in September 2026.
Intellia Therapeutics's investors include Novartis, OrbiMed, Foresite Capital, Fidelity, EcoR1 Capital.
Intellia Therapeutics is headquartered in Cambridge, United States.
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Intellia Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Intellia Therapeutics — Funding & Investors." VCBacked, September 4, 2026, https://www.vcbacked.co/company/intellia-therapeutics. Accessed November 15, 2026.
VCBacked. (2026). Intellia Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/intellia-therapeutics
{{cite web |title=Intellia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/intellia-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Intellia Therapeutics? Request a listing update